To the authors' knowledge, health-related quality of life (HRQOL) outcomes are not well described in patients with medulloblastoma. The use of proton radiotherapy (RT) may translate into an improved HRQOL. In the current study, the authors report long-term HRQOL in patients with proton-treated pediatric medulloblastoma. METHODS: The current study was a prospective cohort HRQOL study of patients with medulloblastoma who were treated with proton RT and enrolled between August 5, 2002, and October 8, 2015. Both child report and parent-proxy report Pediatric Quality of Life Inventory (PedsQL) surveys were collected at baseline during RT and annually thereafter (score range on surveys of 0-100, with higher scores indicating better HRQOL). Patients were dichotomized by clinical/treatment variables and subgroups were compared. Mixed-model analysis was performed to determine the longitudinal trajectory of PedsQL scores. The Student t test was used to compare long-term HRQOL measures with published means from a healthy child population. RESULTS: Survey data were evaluable for 116 patients with a median follow-up of 5 years (range, 1-10.6 years); the median age at the time of diagnosis was 7.6 years (range, 2.1-18.1 years). At baseline, children reported a total core score (TCS) of 65.9, which increased by 1.8 points annually (P<.001); parents reported a TCS of 59.1, which increased by 2.0 points annually. Posterior fossa syndrome adversely affected baseline scores, but these scores significantly improved with time. At the time of last follow-up, children reported a TCS of 76.3, which was 3.3 points lower than that of healthy children (P 5.09); parents reported a TCS of 69, which was 11.9 points lower than that of parents of healthy children (P<.001). Increased follow-up time from diagnosis correlated with improved HRQOL scores. CONCLUSIONS: HRQOL scores appear to increase over time after treatment in children treated with proton RT for medulloblastoma but remain lower compared with those of parent-proxy reports as well as published means from a healthy normative sample of children. Additional follow-up may translate into continued improvements in HRQOL. Cancer
INTRODUCTION
Medulloblastoma is the most common pediatric malignant brain tumor. 1 It is treated with a combination of surgery, radiotherapy, and chemotherapy. However, these treatments can cause acute and long-term sequelae for survivors of childhood cancer. Common late sequalae of brain irradiation include cognitive deficits, alterations in physical appearance, endocrine dysfunction, and hearing loss. 2 These side effects can adversely affect long-term health-related quality of life (HRQOL). 3, 4 Patient-reported HRQOL currently is recognized as an important metric in survivors of pediatric cancer, and the Children's Oncology Group is incorporating the Pediatric Quality of Life Inventory (PedsQL) HRQOL assessment into its treatment or assessment protocols to better evaluate the effect of these treatments on patients. 5, 6 The use of proton radiotherapy over photon-based radiotherapy has garnered significant attention for the treatment of patients with pediatric medulloblastoma. [7] [8] [9] [10] [11] [12] [13] Proton radiotherapy places the dose more precisely in the target volume and decreases the amount of normal tissue treated in children requiring craniospinal irradiation. Proton radiotherapy also can reduce the amount of brain irradiated during the additional focused radiation to the tumor bed. Dosimetric studies have confirmed equivalency in target volume coverage while sparing normal tissues with the use of proton radiotherapy compared with conventional photon irradiation. [14] [15] [16] Although disease control remains equivalent, evidence is mounting that proton radiotherapy does indeed at least partially mitigate many of the adverse side effects of treatment. 7, [17] [18] [19] [20] [21] Regardless of these gains, it is important to measure the effect of proton radiotherapy on long-term QOL, specifically HRQOL from the perspectives of the patient and parent. Survivors of pediatric brain tumors have poorer HRQOL compared with survivors of other childhood cancers. [22] [23] [24] [25] In both the short and long term, HRQOL is affected by multiple factors, such as the tumor itself, receipt of chemotherapy, 26 extent of surgical resection, 27 and the psychosocial effects of having such a disease. Prior studies have suggested that disease type and treatment intensity affect HRQOL and other toxicities in survivors of brain tumors, 2, 28 and that treatment with protons may improve long-term HRQOL outcomes in proton-treated survivors of medulloblastoma. 29 Herein, we report on the patient-reported and parent-reported HRQOL using the previously validated PedsQL generic core scales (version 4.0) 2, [30] [31] [32] in a cohort of patients with medulloblastoma who were treated on a prospective trial assessing the HRQOL of pediatric patients treated with proton radiotherapy (ClinicalTrials.-gov identifier NCT01115777). In addition, we compare long-term HRQOL measures with those from published means from a healthy child sample.
MATERIALS AND METHODS

Patient Population
In this institutional review board-approved study, we approached 161 eligible English-speaking or Spanishspeaking patients with medulloblastoma who were aged 2 to 18 years and treated with proton radiotherapy at the Massachusetts General Hospital and their parents within 2 weeks of the initiation of radiotherapy. Patients with primitive neuroectodermal tumors (PNETs) also were included in the analysis due to similar treatment regimens. Children aged 2 to 5 years were not eligible for self-report (22 patients) , and some older children were unable to selfreport due to posterior fossa syndrome (PFS) (6 patients). Furthermore, some patients with self-report data (16 patients) had no corresponding parent-proxy report data. The parent who spent the most time with the child was asked to complete the parent-proxy report. Details of the approach and consent process have been published previously. 2, 7 Assessments were available in both English and Spanish, and electronic forms (iPad or e-mail) were offered beginning on June 30, 2014 .
The study population consisted of patients enrolled between August 5, 2002, and October 8, 2015 , with follow-up data collected through July 21, 2016. This study comprised 50 patients with medulloblastoma who also were included in the analysis of our prior pediatric brain tumor population QOL study, 2 but with longer follow-up and more detailed data analysis.
Assessment Schedule
All children were assessed once during their first 2 weeks of radiotherapy and once during their last 2 weeks of radiotherapy (before November 4, 2008, children were assessed 3 times during treatment). Baseline scores were averaged over the number of assessments obtained during treatment. Patients were assessed annually thereafter from 2005 onward. After radiotherapy ended, surveys were administered in-person at the time of annual follow-up or by mail/e-mail with a Research Electronic Data Capture (REDCap) link. Approximately two-thirds of follow-up assessments were completed remotely.
Study Measurement
The PedsQL (version 4.0) is a previously validated instrument 2,30-32 with a generic core scale that can be used for both general healthy populations of children and for populations of children with acute and chronic health conditions. Currently, the PedsQL core can accommodate children as young as 2 years of age and has been validated into adulthood. The infant scales and adult scales were not available when the study opened in 2002, but were incorporated into the study when they became available. 33 The 1-month PedsQL version was used. The PedsQL core survey can generate a total core score (TCS) and 2 summary scores, physical and psychosocial, which are reported in the main text of the article. The psychosocial score can be broken down further into 3 primary subscales consisting of school, social, and emotional subsets. PedsQL scores are scaled from 0 to 100, with a score of 100 indicating the best QOL. Some survey subscales could not be calculated due to questions being left blank.
Clinical and Treatment Data
Clinical data including sex, age, boost volume (whole posterior fossa [WP] vs tumor bed [TB]), PFS, shunt (yes/ no), risk stratification (standard risk vs high risk), M classification, and median household income/socioeconomic status (SES) were abstracted from the clinical data registry. SES was determined by median household income using the patient's zip code. 34 The US median income was estimated to be $54,000 after 2011 and $52,000 before 2011 (https://factfinder.census.gov/faces/nav/jsf/pages/community_facts.xhtml). Of the 8 patients with PNETs, only 3 had follow-up HRQOL scores, and this group was too small to analyze statistically.
Statistical Analysis
Descriptive patient demographics, clinical data, and treatment data are reported in Table 1 . Age was dichotomized to children aged <8 years and those aged >8 years for further analyses based on the approximate median of the cohort. The mean HRQOL scores for the core and all of the subscales including physical, psychosocial, school, emotional, and social were calculated. School, emotional, and social scores are reported in table format in the online Supporting Information. Parent-proxy and child reports were assessed for correlation using the intraclass correlation coefficient.
Mixed linear models were used to analyze the longitudinal trajectory of the PedsQL scores. Patients were dichotomized by the following variables: age (8 years vs > 8 years), boost volume (WP vs TB), PFS, sex, M classification, and SES. Scores for the subgroups were examined and compared. Intercepts were randomly specified for patients, and slopes and patient characteristics were modeled as fixed effects. The Student t test was used to compare the scores with published means from a healthy child sample. 31 Multivariate linear regression models were built to identify predictors of higher scores in the various subscales both at baseline and at the time of last follow-up, and are presented in Table 2 and Supporting Table S1 . Data were analyzed using SAS statistical software (version 9.4; SAS Institute Inc, Cary, North Carolina), with P values based on a 2-sided hypothesis test with significance values of .05. We used a Holm-Bonferroni method to correct the level of type I error for the multiple comparisons made in Tables 3 to 5 and Supporting Tables S2 to S4 . Therefore, some P values that appear statistically significant (ie, < .05) are not deemed significant. 35 
RESULTS
There were 116 patients and/or parents (72%) who agreed to participate and provided written informed consent. The patients consisted of 108 patients with medulloblastoma and 8 patients with PNET. From this group, 851 questionnaires were available (average of 7.3 assessments per child), consisting of 85 patients with child report data at baseline (35 patients with only child baseline reports) and 79 patients with child report at the time of last follow-up (19 patients with only child follow-up reports). There were 110 patients with parent-proxy report data at baseline (35 patients with only parent-proxy baseline reports) and 78 patients with parent-proxy report data at the time of last follow-up (3 patients with only parent-proxy follow-up reports). In total, there were 113 patients who had at least 1 parent-proxy report completed and 107 children who had completed at least 1 child report instrument. The median follow-up was 5 years (mean, 5.03 years; range, 1-10.6 years).
The characteristics of the population are listed in Table 1 . The median age at the time of diagnosis was 7.6 years (range, 2.1-18.1 years), and approximately 45% of patients were female. The median income was estimated by zip code, 34 and was $76,000. Approximately 66% of the population was diagnosed with standard-risk medulloblastoma (vs high-risk disease), and 78% were classified as having M0 disease. The boost volume was the TB in 74% of patients and the WP in 26%. The majority of patients did not have PFS (70%) nor a shunt (82%). 
Comparison With Healthy Children
In comparison with published means from a healthy child sample 31 by child report, at the time of last follow-up, the physical score for the proton-irradiated population with medulloblastoma was statistically significantly worse (-5.4); the other subgroup categories did not reach statistical significance (Table 6 ). By parent-proxy report, all summary domains and subscales were statistically significantly worse.
TCS: Child Report
By child report, the TCS at baseline was 65.9, which increased on average 1.8 points annually (P<.001) ( Table  3) . Within most subgroups, the TCS significantly improved over time, with the exception of high-risk patients and those with a shunt. The children with M 1 medulloblastoma had the only subscore that declined in average HRQOL TCS over time; however, this was not statistically significant (slope, -0.2; P 5 .782). Children with PFS scored 13.5 points lower at baseline compared with those without PFS (56 vs 69.5; P<.001), but the scores for both groups increased over time. The TCS was not affected by age (8 years vs > 8 years), sex, or income at baseline or with mean change per year.
TCS: Parent-Proxy Report
The baseline TCS was 59.1, and increased on average 2.0 points annually (P<.001). All scores significantly improved within subgroups over time. Similar to the child Physical Score: Parent-Proxy Report
Starting at a baseline score of 49.9, physical scores increased in the total sample by 4.0 points per year (P<.001). Similar to the child report, in the parent-proxy report among children with PFS, the baseline physical summary scores were significantly lower compared with Among child reports, psychosocial summary scores improved with time in the total sample (baseline, 70.8; slope, 0.9 [P 5 .006]) (Table 5 ). Other subgroups that significantly improved over time included standard-risk patients, patients with M0 disease, patients who received a WP boost, patients without a shunt, and patients with >the US median household income. There were no statistically significant differences noted with regard to psychosocial scores between subgroups at either baseline or change per year. It is interesting to note that there was no statistically significant difference in baseline or last followup scores noted based on household income (P 5 .363).
Psychosocial Score: Parent-Proxy Report
As per parent-proxy report, males, patients with high-risk medulloblastoma, those who received a WP boost, patients with PFS, patients without a shunt, and those with >the US median household income had statistically significant improvements in their psychosocial scores over time. When comparing patients with different boost fields (WP vs TB), patients with a WP boost had significantly greater improvements in their psychosocial score with time (slope of 2.2 vs 0.1; P<.001). However, the mean follow-up for patients who received a WP boost was 6.4 years, whereas the mean follow-up for those who received a TB boost was 4.7 years (P 5 .024).
Correlation Between Child and Parent-Proxy Report
Although the parents typically reported significantly lower TCS than their child did at baseline and at the time of last follow-up, the 2 were highly correlated at all time points (intraclass correlation coefficient, 0.508; P<.001). This same pattern held true for the analysis of physical and psychosocial summary scores as well as the school, social, and emotional subscales (see Supporting Table S5 ).
Multivariable Models
On multivariate analysis and by both child and parentproxy reporting, PFS correlated with a lower total score at baseline, whereas longer follow-up correlated with a higher total score at the time of last follow-up (Table 2 ). For physical scores by both child and parent-proxy reporting, PFS was significantly associated with lower baseline scores, whereas the length of follow-up was significantly associated with higher physical scores. The length of follow-up was significantly associated with higher psychosocial scores as per child report.
DISCUSSION
To our knowledge, the current study of HRQOL in survivors of medulloblastoma is the largest series to date reporting mature (average of 5 years) outcomes and is unique in the medical literature. This cohort can serve as a benchmark and comparator group for other studies such as the Children's Oncology Group ACNS0331 and ACNS0332 average-risk and high-risk medulloblastoma studies, which also are incorporating the PedsQL as a HRQOL metric (directly or through co-enrollment on the ALTE07C1 study) and can help to answer comparative effectiveness questions between proton and photon radiotherapy cohorts in the future. A key finding of the current study is that HRQOL is fairly low at the time of diagnosis and during treatment but continues to rise with time, both by child and parentproxy reports; this was true for the total score as well as the physical and psychosocial summary scores. In addition, PFS was associated with decreased baseline scores, but scores increased steadily over time. PFS was found to be a significant determinant of HRQOL at baseline but improved during follow-up on both univariate and multivariable analysis (see Supporting Information), most likely reflecting the relatively reversible nature of the disorder and adaptation to residual disability.
Another important finding was that the longer the follow-up, the greater the improvement in HRQOL, which was true for total scores as well as the physical and psychosocial summary scores. Presumably, the increase will stabilize, but based on the current study data averaging 5 years of follow-up, we are unable to comment on when that timepoint will occur. Physical HRQOL may especially continue to improve because long-term issues in organs anterior to the spine appear to be reduced among patients who receive proton irradiation. 7 For example, there were no recorded long-term cardiac or pulmonary toxicities in the patients treated with proton radiotherapy compared with known cardiac and pulmonary toxicities that have been reported to occur in 24% to 50% of long-term survivors treated with craniospinal photon irradiation. [36] [37] [38] There were no new cases of gastrointestinal toxic effects such as esophageal strictures or dry mouth, which previously have been recorded in up to 44% of patients treated with photons. 38 It is interesting to note that SES (as estimated by zip code household income) did not affect HRQOL reports in either total scores or physical and psychosocial summary scores on either univariate or multivariate analysis; however, this may be due in part to the inadequate representation of low-income patients in this cohort. In a study from 2012, it was shown that lower income was associated with poorer QOL in children with multiple different types of cancer, without any significant effect noted in healthy children. 39 A surprising finding from the current study was that children who received a WP radiation boost (larger field) had more significant gains in psychosocial scores as per parent-proxy report compared with patients who received a TB radiation boost (smaller field). This unexpected finding may be explained by a combination of 3 factors: 1) follow-up for patients receiving a WP boost was 1.7 years longer, which was found to be significantly correlated with score improvements on multivariable analysis; 2) patients receiving a WP boost had lower baseline scores and patients who started with lower scores tended to experience faster increases; and 3) patients receiving a WP boost were approximately 2 years older at the time of treatment, which may decrease late effects due to more advanced brain development at the time of treatment.
In the current study, the parent-proxy report of child HRQOL was lower than that of the child report but always highly correlated, which is consistent with what has been found in prior studies, and is an important takeaway point. 2, [40] [41] [42] [43] This may be due in part to parents having a different perspective of their child's disease and its potential implications. However, despite the more negative outlook on all scores, the high correlation between the child and parent-proxy reports gives confidence that the parent-proxy report is a good alternative in cases in which children are unable to complete their individual survey.
In comparison with healthy children from studies in the published literature, 31 the current study population of survivors of medulloblastoma scored significantly lower in all subscores by parent-proxy report at the time of last follow-up, but only statistically significantly lower in the physical summary score as per child report. This is promising, especially from the child's standpoint, in that they do not perceive their HRQOL to be substantially different from that of other children, except in the physical capability domain. Nevertheless, there clearly remains much room for improvement in HRQOL scores based on parent-proxy reporting, and the oncology community should continue to strive for more effective and less toxic therapies.
There are several limitations to the current study that merit discussion. Longer follow-up is needed to understand late treatment effects and to better understand the trajectory of the score improvements. Moreover, the contemporary comparison with photon-treated patients with medulloblastoma will be important to understand the different HRQOL outcomes by treatment modality. Another limitation is that not all children could provide a child report, either due to young age or neurologic impairment, but we were able to capture their HRQOL through parent-proxy reports that we and others have found to be highly correlated, albeit somewhat lower. Another limitation is that we failed to capture approximately 30% of eligible patients and there could be differences in QOL among the patients who did not participate that are not captured in the surveys. However, a response rate of approximately 70% typically is deemed acceptable, without resulting in significant bias between participants and nonparticipants. 44, 45 The results of this unique, mature, prospective study of HRQOL in a cohort of patients with medulloblastoma who were treated with proton radiotherapy demonstrate that HRQOL scores improve with time, despite the intensive treatment these individuals received. The biggest determinant of low baseline scores was PFS, and increasing time from treatment was associated with greater gains in HRQOL. Surprisingly, SES did not appear to significantly affect HRQOL scores. Although parent-proxy reports demonstrated lower HRQOL scores, the parentproxy and child scores were highly correlated, indicating that the parent-proxy report is useful when the child is unable to self-report. Because to our knowledge we are the first to report mature outcomes in a medulloblastoma cohort, these data can be used as a benchmark for other studies such as the COG ACNS 0331, which administers the PedsQL in the standard-risk medulloblastoma population at various time points, including at 5 years of follow-up. Because the vast majority of patients on the ACNS 0331 trial were treated with photon radiotherapy, this study sets the stage for a robust and contemporary comparative effectiveness analysis of radiation modality. Continued follow-up is warranted to further elucidate additional long-term effects on HRQOL.
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